Cost-effectiveness of strategies preventing late-onset infection in preterm infants

Alessandro Grosso,1 Rita Isabel Neves de Faria,1 Laura Bojke,1 Chloe Donohue,2 Caroline Isabel Fraser,3 Katie L Harron,3 Sam J Oddie,4,5 Ruth Gilbert6

ABSTRACT

Objective Developing a model to analyse the cost-effectiveness of interventions preventing late-onset infection (LOI) in preterm infants and applying it to the evaluation of anti-microbial impregnated peripherally inserted central catheters (AM-PICCs) compared with standard PICCs (S-PICCs).

Design Model-based cost-effectiveness analysis, using data from the Preventing infection using Antimicrobial Impregnated Long Lines (PREVAIL) randomised controlled trial linked to routine healthcare data, supplemented with published literature. The model assumes that LOI increases the risk of neurodevelopmental impairment (NDI).

Setting Neonatal intensive care units in the UK National Health Service (NHS).

Patients Infants born ≤32 weeks gestational age, requiring a 1 French gauge PICC.

Interventions AM-PICC and S-PICC.

Main outcome measures Life expectancy, quality-adjusted life years (QALYs) and healthcare costs over the infants’ expected lifetime.

Results Severe NDI reduces life expectancy by 14.79 (95% CI 4.43 to 26.68; undiscounted) years, 10.63 (95% CI 7.74 to 14.02; discounted) QALYs and costs £190.57 (95% CI £141.97; £246.97; discounted) to the NHS. If LOI causes NDI, the maximum acquisition price of an intervention reducing LOI risk by 5% is £120. AM-PICCs increase costs (£54.85 (95% CI £25.95 to £89.12)) but have negligible impact on health outcomes (−0.01 (95% CI −0.09 to 0.04) QALYs), compared with S-PICCs. The NHS can invest up to £2.4 million in research to confirm that AM-PICCs are not cost-effective.

Conclusions The model quantifies health losses and additional healthcare costs caused by NDI and LOI during neonatal care. Given these consequences, interventions preventing LOI, even by a small extent, can be cost-effective. AM-PICCs, being less effective and more costly than S-PICCs, are not likely to be cost-effective.

Trial registration number NCT03260517.

INTRODUCTION

Preterm infants hospitalised in neonatal intensive care units (NICUs) often require a peripherally inserted central catheter (PICC) to receive medicines, fluids and parenteral nutrition.1 PICCs provide a conduit for microorganisms to enter the bloodstream and a site where microorganisms can proliferate, increasing the risk of late-onset infection (LOI). LOI has been linked to higher risk of death and permanent neurodevelopmental impairment (NDI).2,3 Furthermore, treating LOI with antibiotics is harmful to the developing gut microbiome,4 potentially leading to serious conditions such as necrotising enterocolitis.5,7

Antimicrobial impregnated PICCs (AM-PICCs) have been shown to prevent LOI in adults and children but evidence is sparse in preterm infants.8 To address this evidence gap, the PREVAIL trial (NIHR HTA 12/167/02) investigated the safety, effectiveness and cost-effectiveness of AM-PICCs versus standard non-impregnated PICCs (S-PICCs) in reducing LOI in prematurity.9

This study reports the cost-effectiveness model to establish the long-term value of preventing LOI in preterm infants hospitalised in NICUs, and its application to estimate the cost-effectiveness of AM-PICCs versus S-PICCs. The model uses data from PREVAIL, linked to hospital use collected from the UK National Neonatal Research Database (NNRD), Hospital Episode Statistics (HES) and Paediatric Intensive Care Network (PICAnet) to estimate costs, alongside evidence from the external...
literature on the long-term health and economic consequences of LOI.

**METHODS**

A new decision analytic model was developed to simulate the lifetime costs, life expectancy and quality-adjusted life years (QALYs) of infants born ≤32 weeks gestational age (GA) who required a PICC during their NICU stay. Given the impact of GA on health outcomes, results are presented for two subgroups: GA 23–27 weeks and GA 28–32 weeks. Costs are expressed in UK pound sterling at a 2016 price base, from the perspective of the UK NHS. Future costs and QALYs are discounted at 3.5% per annum. The model was developed using Microsoft Excel.

**Model structure**

The model structure is represented in figure 1. Infants enter the model at the time of PICC insertion and are at risk of LOI. LOI increases the risk of death and NDI (but not its severity). At 2 years of age, children are assessed for the presence and severity of NDI. From age 2 onwards, the model follows the same structure as the model by Mangham et al, which estimated the costs of prematurity. Children transition between NDI states or die. The transitions represent improvement or deterioration in NDI status, as well as inaccuracies in the assessment, which might appear over time. After reaching age 8, children remain at risk of death but their NDI level is assumed to remain stable.

**Model parameterisation**

Model parameters are presented in table 1. LOI corresponds to clinically serious bloodstream infection in the PREVAIL trial (subgroup with GA ≤32 weeks), a pragmatic randomised controlled trial performed across 18 NICUs in England. Infants requiring a narrow (1 French) gauge PICC were considered eligible and once enrolled in the trial were allocated 1:1 to receive either a PICC impregnated with miconazole and rifampicin (AM-PICC) or an S-PICC. Clinically serious bloodstream infection, defined as positive blood/cerebrospinal fluid culture and >72 hours treatment with intravenous antibiotic, or death during treatment, was thought to be closer to the definition of LOI in the literature than PREVAIL’s primary outcome of any positive blood/cerebrospinal fluid culture. The probability of death at 6 months was informed by an observational study covering all NICUs in England, for a total of 7369 hospitalised infants in 2014; details in online supplementary material 1. The probability of death between 6 months and 2 years of age if infants had received S-PICC was sourced from Mangham et al, and based on data from the ‘91–’92 Victorian Infant Collaborative Study Cohort. The probability of death from age 2 was obtained from the UK lifetables 2013–15, to which the excess risk due to NDI was added; see online supplementary material 2.

A pearl growing review and meta-analysis was conducted to estimate the effect of LOI on death and NDI; details in online supplementary material 4. The search started from Stoll et al, a US observational study linking LOI to death and NDI. Studies were selected if their definition of LOI was consistent with the PREVAIL trial, and if their definition of NDI was consistent with Mangham et al. Three systematic reviews were identified, from which Schlapbach et al and Bassler et al were selected. Stoll et al and Schlapbach et al were meta-analysed to inform the added risk of developing NDI at 2 years of age given LOI (1.51, 95% CI 1.33 to 1.70), while Schlapbach et al and Bassler et al were meta-analysed to inform the added risk of death between 6 months and 2 years of age, given LOI (2.74, 95% CI 1.43 to 5.24).

**Costs**

The cost of S-PICC and AM-PICC was provided by the manufacturer (personal communication). Costs between PICC insertion and 6 months were calculated using routine healthcare data of the infants enrolled in the PREVAIL trial: NNRI for the NICU stay, PICANet for stays in the paediatric intensive care unit, HES inpatient, HES outpatient and accident and emergency. Details of all data items are searchable at NHS Reference Cost 15/16. For the base-case, costs depend only on GA. For details, see online supplementary material 5.
Table 1  Model parameters

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value GA 23–27 weeks (95% CI; distribution)</th>
<th>Value GA 28–32 weeks (95% CI; distribution)</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>Effect of AM-PICC on the probability of LOI</td>
<td>Relative risk of AM-PICC vs S-PICC 1.06 (0.70 to 1.60; lognormal)</td>
<td>PREVAIL trial (subgroup of infants born ≤32 weeks GA), Mangham et al.6</td>
<td></td>
</tr>
<tr>
<td>Effect of LOI on NDI and death</td>
<td>Relative risk of the effect of LOI on death at 6 months 1 (fixed)</td>
<td>Assumed that LOI has no effect on death at 6 months in the base case.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>OR for the effect of LOI on NDI at 2 years of age 1.51 (1.33 to 1.70; lognormal)</td>
<td>Meta-analysis of Stoll et al.28 and Schlapbach et al.29</td>
<td></td>
</tr>
<tr>
<td></td>
<td>OR for the effect of LOI on death at 2 years of age 2.74 (1.43 to 5.24; lognormal)</td>
<td>Meta-analysis of Schlapbach et al.28 and Baslier et al.29</td>
<td></td>
</tr>
<tr>
<td>Probabilities using S-PICC</td>
<td>Probability of LOI 0.14 (0.09 to 0.20; beta) 0.04 (0.02 to 0.08; beta)</td>
<td>PREVAIL trial (subgroup of infants born ≤32 weeks GA), Santhakumaran et al.13</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Probability of death between PICC insertion and 6 months 0.20 (0.16 to 0.23; beta) 0.03 (0.03 to 0.04; beta)</td>
<td>Mangham et al.12 Estimates refer to a population of infants with different LOI status and applied to the non-infected infants (see online supplementary material 1).</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Probability of death between 6 months and 2 years 0.02 (0.01 to 0.03; beta) 0.01 (0.00 to 0.02; beta)</td>
<td>Mangham et al.12 Estimates refer to a population of infants with different LOI status and applied to the non-infected infants.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Probability of developing NDI 0.45 (0.42 to 0.49; dirichlet) 0.26 (0.25 to 0.28; dirichlet)</td>
<td>Mangham et al.12 assumed to be similar for both sepsis and non-sepsis groups. Severe NDI calculated as the complement.</td>
<td></td>
</tr>
<tr>
<td>Distribution by NDI levels, given that NDI occurred</td>
<td>Mild NDI 0.54 (0.51 to 0.58; dirichlet) 0.73 (0.70 to 0.76; dirichlet)</td>
<td>Mangham et al.12</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Moderate NDI 0.29 (0.28 to 0.30; dirichlet) 0.16 (0.15 to 0.17; dirichlet)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Health-related quality of life (to calculate QALYs)</td>
<td>No NDI 0.96 (0.94 to 0.97; beta)</td>
<td>Petrou et al.28</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mild NDI decrement 0.18 (0.14 to 0.31; gamma)</td>
<td>Petrou et al.28</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Moderate NDI decrement 0.30 (0.24 to 0.46; gamma)</td>
<td>Petrou et al.28</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Severe NDI decrement 0.56 (0.44 to 0.77; gamma)</td>
<td>Petrou et al.28</td>
<td></td>
</tr>
<tr>
<td>Costs</td>
<td>Difference in cost between PICCs (AM-PICC vs S-PICC) £53.70</td>
<td>Personal communication from the manufacturer</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Healthcare costs between PICC insertion and 6 months £105,873.47 (101 444.99 to 110 495.27; gamma) £62,255.37 (54 711.87 to 70 838.93; gamma)</td>
<td>PREVAIL trial and linked datasets (NNRD, PICANet, HES), NHS Reference Cost 15/1627 derived from HES inpatient, A&amp;E and outpatient data.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Healthcare costs between 6 months and 2 years £5899.17 (£5989.14 to £5949.98) £3026.17 (£3026.43 to £3028.73)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Annual costs between age 2 and 10 years</td>
<td>No NDI £388 (£285 to £509; gamma)</td>
<td>Petrou et al.28; inflated to 2016</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mild NDI £753 (£584 to £946; gamma)</td>
<td>Petrou et al.28; inflated to 2016</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Moderate NDI £814 (£560 to £1063; gamma)</td>
<td>Petrou et al.28; inflated to 2016</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Severe NDI £1487 (£1096 to £1943; gamma)</td>
<td>Petrou et al.28; inflated to 2016</td>
<td></td>
</tr>
<tr>
<td>Annual costs after age 11 years</td>
<td>No NDI £686 (£400 to £993; gamma)</td>
<td>Petrou et al.28; inflated to 2016</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mild NDI £987 (£782 to £1222; gamma)</td>
<td>Petrou et al.28; inflated to 2016</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Moderate NDI £1252 (£933 to £1624; gamma)</td>
<td>Petrou et al.28; inflated to 2016</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Severe NDI £1976 (£1411 to £2648; gamma)</td>
<td>Petrou et al.28; inflated to 2016</td>
<td></td>
</tr>
</tbody>
</table>

Costs between 6 months and 2 years of age were calculated from the use of hospital care by preterm infants derived from HES inpatient, A&E and outpatient data, costed with NHS Reference Costs 15/16.27 For details, see online supplementary material 6.

Annual costs by NDI level between 2 and 10 years of age were sourced from Mangham et al.12 which reports the results from the EPICure cohort at 6 years of age.28 The annual costs by NDI level ≥11 years of age related to the same EPICure cohort, obtained from Petrou et al.29 Costs from age 2 refer to any healthcare costs, both related and unrelated to NDI

Health-related quality of life

Health-related quality of life by NDI level was obtained from Petrou et al.29 which collected Health Utilities Index (HUI) Mark 3 at 11 years of age from parents of infants in the EPICure cohort. The HUI scores are applied throughout lifetime, and no additional decrement has been added to consider additional comorbidities due to, for example, age, given the lack of published estimates for people with NDI.

Analytical methods

Simulation methods were used to generate mean costs, life years and QALYs.30 The model estimated outcomes and costs given different levels of NDI at age 2, conditional on whether LOI occurred during the NICU stay, and by PICC type. The utility of the model in establishing which intervention is cost-effective was illustrated by the comparison between AM-PICC and S-PICC. The cost-effective intervention is the one which achieves the most health benefits given its costs and the cost-effectiveness

GA, gestational age; HES, Hospital Episode Statistics; LOI, late-onset infection; NDI, neurodevelopmental impairment; NHS, National Health Service; NNRD, National Neonatal Research Database; PICANet, Paediatric Intensive Care Network; PICC, peripherally inserted central catheter; QALY, quality-adjusted life year.

threshold of £20 000/QALY, a benchmark of the maximum acceptable added cost per QALY gained commonly used for the UK NHS. The robustness of the results was assessed by varying the parameter values over the 95% CI and with scenario analysis. For details, see online supplementary material 8. The model was validated using the Advishe checklist, see online supplementary material 9.

Exploring the value of further research
The model can calculate the health benefits of knowing which is the cost-effective intervention with absolute certainty (ie, with perfect information), the ‘expected value of perfect information’ (EVPI). Using the cost-effectiveness threshold as the monetary value of 1 QALY, the health benefits can be converted to monetary units. This represents the most that the UK NHS should invest in future research to inform a policy decision. The EVPI was calculated considering the uncertainty around all parameters informing the model and for each individual parameter. It is presented for the preterm infant population in England over 10 years, assuming that this is the population who would benefit from any future research. The calculations were conducted using the online SAVI simulator.

RESULTS

Long-term value of preventing NDI
Figure 2 shows the outcomes by NDI level over the infants’ expected lifetime. The model predicts that, as the NDI level worsens, life expectancy and QALYs reduce, while costs increase. The long-term value of preventing NDI can be computed as the difference between the predicted QALYs and costs with and without impairment. As an example, the difference in costs and health outcomes between mild and no NDI is £3690 lower costs and 2.16 additional QALYs. If a QALY is valued at £20 000, avoiding mild NDI in one child warrants up to £46 890 (2.16 QALYs×£20 000+£3690) in investment by the NHS.

Sensitivity analysis
The results were robust to all sensitivity analyses and scenarios apart from varying the effect of AM-PICC in preventing LOI, and, to a smaller extent, the effect of LOI on the risk of death. For details, see online supplementary material 8.

Cost-effectiveness of an intervention to prevent LOI: AM-PICC versus S-PICC
The model can be used to analyse the cost-effectiveness of any intervention to prevent LOI in preterm infants during their stay in the NICU. To illustrate, table 2 shows the results of the cost-effectiveness analysis comparing AM-PICC with S-PICC. As expected given the results of the PREVAIL trial, AM-PICC is not cost-effective.

Table 2 Cost-effectiveness results

<table>
<thead>
<tr>
<th>Cost-effectiveness results</th>
<th>Gestational age (weeks)</th>
<th>23–27</th>
<th>28–32</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>AM-PICC</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total costs (95% CI)</td>
<td>£127 183 (120 983 to 133 919)</td>
<td>£83 588 (77 048 to 90 839)</td>
<td></td>
</tr>
<tr>
<td>Total QALYs (95% CI)</td>
<td>16.48 (15.41 to 17.59)</td>
<td>21.46 (20.67 to 22.17)</td>
<td></td>
</tr>
<tr>
<td><strong>S-PICC</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total costs (95% CI)</td>
<td>£127 128 (120 936 to 133 866)</td>
<td>£83 533 (76 994 to 90 784)</td>
<td></td>
</tr>
<tr>
<td>Total QALYs (95% CI)</td>
<td>16.49 (15.44 to 17.60)</td>
<td>21.46 (20.67 to 22.17)</td>
<td></td>
</tr>
<tr>
<td><strong>AM-PICC vs S-PICC</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cost difference (95% CI)</td>
<td>£55 (26 to 89)</td>
<td>£55 (48 to 64)</td>
<td></td>
</tr>
<tr>
<td>QALY difference (95% CI)</td>
<td>−0.01 (−0.09 to 0.04)</td>
<td>0.00 (−0.01 to 0.01)</td>
<td></td>
</tr>
<tr>
<td>Incremental net health benefit at £20 000/QALY</td>
<td>−0.01 (−0.09 to 0.04)</td>
<td>−0.01 (−0.02 to 0.00)</td>
<td></td>
</tr>
</tbody>
</table>

AM-PICC, antimicrobial impregnated PICC; PICC, peripherally inserted central catheter; QALY, quality-adjusted life year; S-PICC, standard PICC.
DISCUSSION
Summary of findings
A new decision analytic model was developed to predict the quality-adjusted life expectancy and lifetime NHS costs of infants using AM-PICC or S-PICC. Based on existing literature, the model assumes that LOI negatively affects health outcomes. Under this assumption, a strategy to prevent LOI is valuable as it can lead to an increase in life expectancy, health-related quality of life and a reduction in costs. AM-PICCs, however, being more costly and with no evidence of benefits over S-PICCs, are not cost-effective. Whether more research on the effectiveness of AM-PICC versus S-PICC is cost-effective depends on the cost and the design of future trials.

Strengths
This study represents the first attempt at estimating the cost-effectiveness of AM-PICCs in the NICU setting. Available studies on impregnated PICCs considered older populations and different antimicrobials agents, precluding meaningful comparisons. The model synthesises relevant information on the costs and consequences of LOI. It is flexible so that it can be used to evaluate the cost-effectiveness of any other intervention to prevent LOI during a NICU stay, informing various policy decisions, that is, whether new interventions should be adopted and how much to invest in future research.

Limitations
The causal effect of LOI on death and hospital costs could not be estimated given the small number of deaths. Consequently, the model base-case assumes that infants incur the same costs irrespective of LOI or survival status, and that LOI does not increase the risk of death at 6 months. These assumptions were tested in a scenario analysis, and in the comparison between AM-PICC and S-PICC, they had no impact on the results. If LOI is linked with higher costs and higher risk of death during the NICU stay, its prevention can be linked to greater health and economic benefit than those estimated above.

The model assumes that LOI increases the risk of death and NDI at 2 years of age, based on publications identified from a non-systematic citation search. Despite the nature of the searches, three systematic reviews were identified and screened, providing reassurance that all relevant primary studies were identified. The limitation is that the association between LOI and NDI/death may not be causal, given the observational nature of the data. The impact of varying the effect of LOI on cost-effectiveness results was small, but this is likely to be related to the limited difference between AM-PICC and S-PICC in preventing LOI. Future cost-effectiveness analyses of other interventions to prevent LOI should conduct sensitivity analyses for these parameters.

The model structure constrains the impact of preventing LOI to reducing the risk of NDI and death at 2 years of age. Some studies suggest that the impact of LOI on NDI is mediated via necrotising enterocolitis. Given that no studies were identified that disentangled the direct effect of LOI on NDI from the indirect effect via antibiotic treatment, necrotising enterocolitis was not modelled explicitly.

This study takes the perspective of the NHS for costs and benefits following the National Institute for Health and Care Excellence guidance to evaluate interventions funded by the NHS. This covers hospital costs and costs of community healthcare. It was not possible to include the latter over the time period from PICC insertion to 2 years of age due to a lack of comprehensive routine healthcare databases which compile such data. Costs falling on other sectors, such as social care and education, are likely to be relevant, but fall outside the NHS perspective. The study considers the impact of LOI on the infants’ length and health-related quality of life only. Health outcomes experienced by infants and children may have spill over effects to their family and carers, which were not accounted for here.

Acknowledgements
The authors would like to thank Vygon for allowing participating sites to purchase the impregnated lines at a reduced cost for the duration of the study and informing them of the list price of the lines. Through the PREVAIL Trial Management Group, particularly Jon Dorling and Ajay Sinha for helpful discussions on the model structure and its clinical validity; María José Aragón for assistance in the HES data; Lee Norman and Roger Parlow at PICANet for their help in providing data; Kayleigh Ougham and Richard Colquhoun at NDAU for their help in providing and answering our questions about the data; Micaela Brown, Naomi Rainford, Tracy Mott, Corral Gamble and Duncan Appelbe at the University of Liverpool for their work in the PREVAIL trial and providing the PREVAIL trial data; all contract teams at the University of York, University of Liverpool, University College London and Imperial College London for their help with the data sharing arrangements. Stavros Petrou for helpful discussions on data sources to inform the model; Nicky Welton and Caroline Clarke for an excellent discussion of our paper at the Health Economics Study Group Summer 2018 meeting and at the 5th EuHEA PhD Student-Supervisor Conference, respectively and all the colleagues who took part in the discussion. The authors would like to thank all the families that agreed to the inclusion of their baby’s data in the NNRD, the health professionals who recorded data and the NDAU team.

Contributors
AG, RINdeF and LB conceptualised the model with valuable input from SJO and RG. CD, CIF and KLH provided valuable assistance in obtaining access to the data. AG and RINdeF performed the main analysis with support from LB. All authors provided input in the interpretation of the study results. AG led the drafting of the manuscript with support from RINdeF and LB. All authors contributed to the editing of the manuscript. All authors read and approved the final manuscript.

Funding
This research was funded by the National Institute for Health Research (NIHR)—Health Technology Assessment (HTA) Programme 12/16/02. AG is funded by the National Institute for Health Research (NIHR)—Research Methods Fellowship Programme NIHR-RMF1-2016-07-16.

Disclaimer
Access to the fully anonymised PREVAIL Trial datasets and data dictionary can be obtained by applying to the Clinical Trials Research Centre (University of Liverpool, Liverpool, UK), who will liaise with the investigators to approve the proposal and ensure that a signed data access agreement is in place before releasing the data. Electronic patient data recorded at participating neonatal units that collectively form the United Kingdom Neonatal Collaborative (UKNC) are transmitted to the Neonatal Data Analysis Unit (NDAU) to form the National Neonatal Research Database (NNRD). LB, RINdeF and AG had full access to all the data in the study and take full responsibility for the integrity of the data and accuracy of the data analysis. The Paediatric Intensive Care Audit Network (PICANet) is commissioned by the Healthcare Quality Improvement Partnership (HQIP) as part of the National Clinical Audit and Patient Outcomes Programme (NCAPO), the Welsh Health Specialised Services, NHS Lothian/National Services Division and NHS Scotland, the Royal Belfast Hospital for Sick Children, The National Office of Clinical Audit (NOCA), Republic of Ireland and HCA Healthcare UK. HQIP is led by a consortium of the Academy of Medical Royal Colleges, the Royal College of Nursing and National Voices. Its aim is to promote quality improvement in patient outcomes, and in particular, to increase the impact that clinical audit, outcome review programmes and registries have on healthcare quality in England and Wales. HQIP holds the contract to commission, manage and develop the NCAPO, comprising around 40 projects covering care provided to people with a wide range of medical, surgical and mental health conditions. The programme is funded by NHS
England, the Welsh Government and, with some individual projects, other devolved administrations and crown dependencies. www.hqip.org.uk/national-programmes. This research was informed by data collected by NHS Digital (former Health and Social Care Information Centre). Copyright 2015–2018, the Health and Social Care Information Centre. Re-used with the permission of the Health and Social Care Information Centre. All rights reserved.

Competing interests None declared.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available on reasonable request. Data may be obtained from a third party and are not publicly available.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.

ORCID iDs
Alessandro Grosso http://orcid.org/0000-0001-7211-438X
Rita Isabel Neves de Faria http://orcid.org/0000-0003-3410-1435
Katie L Harron http://orcid.org/0000-0002-3418-2856

REFERENCES